Evelo Biosciences Fails to Meet Primary Endpoint in Phase 2 Study

Evelo Biosciences (Nasdaq: EVLO) has failed to meet its primary endpoint in its Phase 2 trial of EDP1815 as a treatment in atopic dermatitis.

The company intends to turn its focus to EDP2939 currently in a Phase 1/2 study in psoriasis.

Highlights

The study’s primary endpoint was the proportion of patients who achieved at least a 50% improvement from baseline in Eczema Area and Severity Index (EASI) score at week 16.

Evelo will cease further development of EDP1815 in atopic dermatitis following a wind-down of the study.

The company’s Phase 2 study of EDP2939 in moderate psoriasis is now fully enrolled, and Evelo expects to report topline results early in the fourth quarter of this year.

Dr. Simba Gill, CEO of Evelo expressed his sincere thanks to the patients and clinicians involved in the company’s studies and to our team for advancing its programs.

About Evelo Biosciences

Evelo Biosciences is a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects. The small intestine plays a central role in governing inflammation throughout the body. The Company’s product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Evelo’s vision is to create therapies that are effective, safe, well-tolerated, and affordable to improve the lives of the billions of people living with inflammatory diseases. If shown to be effective in inflammatory disease mediated by the Th1, Th2 or Th17 inflammatory pathways, these same investigational medicines could be effective in additional inflammatory diseases, such as psoriatic and other forms of arthritis, asthma, allergy, and inflammatory bowel disease.